Multiple Sclerosis Discovery Forum

Inspiring Connections

Sort By: Most Recent Article / Most Recent Comments / Most Comments

News Briefs | 23 Apr 2014

MS Research Roundup: April 23, 2014

Human Versus Mouse Microglia; Teva Suffers Setback in Generic Copaxone Fight; Motley Fool Loves Biogen Idec

Carol Cruzan Morton

Items of interest to multiple sclerosis researchers from around the Web...

Clinical Research, Drug Development, Laboratory Research

News Briefs | 18 Apr 2014

MS Research Roundup: April 18, 2014

Progress Toward New MS Clinical Trial Outcomes; Adaptive Design Evolves; A Call for Fundamental Neuroscience Research; MS Miracle Cures

Carol Cruzan Morton

Items of interest to multiple sclerosis researchers from around the Web...

Clinical Research, Drug Development, Laboratory Research, People

News Briefs | 15 Apr 2014

Antibody Testing Affects MS Therapy Management

In a randomized trial, access to antibody testing affected MS management. Serum binding antibodies predicted positivity to neutralizing antibodies in patients on high-dose interferon.

Laurie Barclay, M.D.

Access to antibody testing affected management in persons with multiple sclerosis, according to findings from...

Clinical Research

News Briefs | 10 Apr 2014

Stopping Natalizumab May Increase Risk of MS Relapse

The RESTORE trial showed that MRI and clinical MS activity recurred during natalizumab interruption in some patients who had been relapse-free for 1 year

Laurie Barclay, M.D.

Despite use of other therapies, magnetic resonance imaging and clinical activity of multiple sclerosis recurred during...

Clinical Research

News Briefs | 4 Apr 2014

MS Research Roundup: April 4, 2014

Embryonic Stem Cells Need Ancient Viral Remnants; Collaborating on Cures; Copaxone Goes to Highest Court

Carol Cruzan Morton

Items of interest to multiple sclerosis researchers from around the Web...

Drug Development, Laboratory Research

News Briefs | 2 Apr 2014

PPMS: Predictors of Disease Progression Still Unknown

Failure to find reliable progression predictors makes individualized risk counseling difficult, highlights the shortcomings of the EDSS, and may complicate future PPMS clinical trials

Laurie Barclay, M.D.

None of the variables analyzed in a large cohort of patients with primary-progressive multiple sclerosis predicted...

Clinical Research

News Briefs | 31 Mar 2014

MS Research Roundup: March 31, 2014

Tracking Research in Social Media; Faster Cures Through Online Collaboration; The MS Athletic Edge

Carol Cruzan Morton

Items of interest to multiple sclerosis researchers from around the Web...

People

News Briefs | 23 Mar 2014

MS Research Roundup: March 21, 2014

Tests of HIV Drug in Progress for RRMS; Statin Discovery in Progressive MS; Bench-to-Bedside MS Research Talks Online

Carol Cruzan Morton

Items of interest to multiple sclerosis researchers from around the Web...

Clinical Research, Drug Development, Meetings

News Briefs | 20 Mar 2014

Atacicept Phase 2 Trial Yields Disappointing Results for MS

Atacicept, which targets B cells, increased rather than decreased exacerbations in relapsing MS

Steven Fox

Results from a phase 2 trial of the recombinant fusion protein atacicept raise significant questions about...

Clinical Research, Drug Development

News Briefs | 11 Mar 2014

Complementary/Alternative Medicine Use Changes With MS Progression

The transition from moderate to severe impairment is when many MS patients turn to complementary or alternative medicine

Laurie Barclay, M.D.

Persons with MS use complementary and alternative medicine most often during...

Clinical Research